ELITE PHARMS INC - ELTP STOCK NEWS

Welcome to our dedicated page for ELITE PHARMS news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on ELITE PHARMS stock.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, improving off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. With four ANDA products partnered with Tagi Pharma, Elite is making strides in the pharmaceutical industry. Elite also manufactures Lodrane D® and receives royalties for this allergy product partnered with ECR Pharmaceuticals, a wholly owned subsidiary of Hi-Tech Pharmacal. Their lead pipeline products, Eli-216 and Eli-154, are novel sustained-release oral formulations of opioids for chronic pain treatment.

05/20/2024 06:00 AM

News

Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate

Rhea-AI Summary

Elite Pharmaceuticals announced FDA approval for its generic Methotrexate Sodium 2.5 mg tablets. This approval relates to an Abbreviated New Drug Application (ANDA) and adds to Elite's portfolio of niche generic products. The generic Methotrexate, classified as an antimetabolite, will be marketed under Elite Laboratories. According to IQVIA, the generic market for Methotrexate had annual sales of $64.3 million for the twelve months ending March 2024. Elite Pharmaceuticals focuses on developing, manufacturing, and distributing immediate-release and controlled-release solid oral dose products, operating from a cGMP and DEA registered facility in Northvale, NJ.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.14%

Tags

02/14/2024 04:30 PM

News

Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information

Rhea-AI Summary

Elite Pharmaceuticals, Inc. reported strong financial results for the third quarter of fiscal year 2024, with consolidated revenues of $15.5 million, a 68% increase from the previous year. Operating profits also rose by 80% to $3.5 million, driven by increased sales of Elite Laboratories label products. A conference call is scheduled for February 15, 2024, to discuss the financial results and recent business developments.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10%

Tags

02/08/2024 08:15 AM

News

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024

Rhea-AI Summary

Elite Pharmaceuticals, Inc. will release its financial results for the third quarter of fiscal year 2024 on February 14, 2024. The company will host a live conference call on February 15th to discuss the results and provide a general business update. Stockholders are encouraged to submit questions before the call.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5%

Tags

12/26/2023 07:00 AM

News

Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant

Rhea-AI Summary

Elite Pharmaceuticals, Inc. (ELTP) announced FDA acceptance for review of an Abbreviated New Drug Application (ANDA) for an undisclosed generic drug product in the central nervous stimulants class. IQVIA reported annual sales of $5.1 billion for the brand and generic market for this product.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/12/2023 07:00 AM

News

Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC

Rhea-AI Summary

Elite Pharmaceuticals, Inc. (ELTP) has announced the first shipment of generic Adderall XR to its partner Prasco, LLC. The extended-release mixed salt of a single entity Amphetamine product will be distributed by Prasco under Burel Pharmaceutical's label, pursuant to the manufacturing and supply agreement between the companies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/14/2023 05:35 PM

News

Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information

Rhea-AI Summary

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Announces Strong Second Quarter Fiscal Year 2024 Results with 64.9% Revenue Increase and 886% Net Income Growth. Conference Call Scheduled for November 15 at 11:30 AM EST to Discuss Financial Results and Business Update.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

16.67%

Tags

11/10/2023 11:30 AM

News

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023

Rhea-AI Summary

Elite Pharmaceuticals, Inc. (OTCBB:ELTP) to Release Q2 Fiscal Year 2024 Financials on November 14, 2023

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/25/2023 06:00 AM

News

Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product

Rhea-AI Summary

Elite Pharmaceuticals files ANDA for generic drug product, FDA accepts for review

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/07/2023 06:00 AM

News

Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer

Rhea-AI Summary

Elite Pharmaceuticals appoints Carter Ward as CFO

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/28/2023 06:00 AM

News

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Rhea-AI Summary

Elite Pharmaceuticals reports positive results from bioequivalence studies for undisclosed generic drug product in CNS stimulants class. IQVIA reports annual sales of $5.1B for this product. Generic product found to be bioequivalent to branded product. Elite plans to file Abbreviated New Drug Application with FDA.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

25%

Tags

FAQ

What is the current stock price of ELITE PHARMS (ELTP)?

The current stock price of ELITE PHARMS (ELTP) is $0.6168 as of November 22, 2024.

What is the market cap of ELITE PHARMS (ELTP)?

The market cap of ELITE PHARMS (ELTP) is approximately 715.7M.

What is Elite Pharmaceuticals, Inc. known for?

Elite Pharmaceuticals, Inc. is known for developing oral sustained and controlled release products, along with improving off-patent drug products and developing generic versions of controlled release drug products.

What are Elite Pharmaceuticals' lead pipeline products?

Elite Pharmaceuticals' lead pipeline products are Eli-216 and Eli-154, which are novel sustained-release oral formulations of opioids for treating chronic pain.

Who are Elite Pharmaceuticals' key partners?

Elite Pharmaceuticals has partnered with Tagi Pharma for four ANDA products and with ECR Pharmaceuticals for Lodrane D®.

Where is Elite Pharmaceuticals' manufacturing facility located?

Elite Pharmaceuticals' cGMP and DEA registered facility for research, development, and manufacturing is located in Northvale, NJ.

What recent achievement did Elite Pharmaceuticals announce?

Elite Pharmaceuticals recently announced the first shipment of generic Adderall XR® to their partner Prasco, LLC, marking a significant milestone for the company.